Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system.

Autor: Celia C; Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030, USA; Department of Health Sciences, University 'Magna Graecia' of Catanzaro, V.le 'S. Venuta' Germaneto-Catanzaro 88100, Italy., Ferrati S, Bansal S, van de Ven AL, Ruozi B, Zabre E, Hosali S, Paolino D, Sarpietro MG, Fine D, Fresta M, Ferrari M, Grattoni A
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2014 Feb; Vol. 3 (2), pp. 230-8. Date of Electronic Publication: 2013 Jul 23.
DOI: 10.1002/adhm.201300188
Abstrakt: Metronomic chemotherapy supports the idea that long-term, sustained, constant administration of chemotherapeutics, currently not achievable, could be effective against numerous cancers. Particularly appealing are liposomal formulations, used to solubilize hydrophobic therapeutics and minimize side effects, while extending drug circulation time and enabling passive targeting. As liposome alone cannot survive in circulation beyond 48 h, sustaining their constant plasma level for many days is a challenge. To address this, we develop, as a proof of concept, an implantable nanochannel delivery system and ultra-stable PEGylated lapatinib-loaded liposomes, and we demonstrate the release of intact vesicles for over 18 d. Further, we investigate intravasation kinetics of subcutaneously delivered liposomes and verify their biological activity post nanochannel release on BT474 breast cancer cells. The key innovation of this work is the combination of two nanotechnologies to exploit the synergistic effect of liposomes, demonstrated as passive-targeting vectors and nanofluidics to maintain therapeutic constant plasma levels. In principle, this approach could maximize efficacy of metronomic treatments.
(Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
Databáze: MEDLINE
Externí odkaz: